AU2004216360B2 - Pharmaceutical composition for treatment of drug dependence - Google Patents
Pharmaceutical composition for treatment of drug dependence Download PDFInfo
- Publication number
- AU2004216360B2 AU2004216360B2 AU2004216360A AU2004216360A AU2004216360B2 AU 2004216360 B2 AU2004216360 B2 AU 2004216360B2 AU 2004216360 A AU2004216360 A AU 2004216360A AU 2004216360 A AU2004216360 A AU 2004216360A AU 2004216360 B2 AU2004216360 B2 AU 2004216360B2
- Authority
- AU
- Australia
- Prior art keywords
- mice
- dependence
- cocaine
- morphine
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44986803P | 2003-02-27 | 2003-02-27 | |
| US60/449,868 | 2003-02-27 | ||
| PCT/JP2004/002301 WO2004075916A1 (en) | 2003-02-27 | 2004-02-26 | Pharmaceutical composition for treatment of drug dependence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2004216360A1 AU2004216360A1 (en) | 2004-09-10 |
| AU2004216360A2 AU2004216360A2 (en) | 2004-09-10 |
| AU2004216360B2 true AU2004216360B2 (en) | 2009-09-17 |
Family
ID=32927586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004216360A Ceased AU2004216360B2 (en) | 2003-02-27 | 2004-02-26 | Pharmaceutical composition for treatment of drug dependence |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060058336A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1603595B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006519225A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE487492T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004216360B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2516618A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004029993D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004075916A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| AU2002340232A1 (en) * | 2001-10-17 | 2003-04-28 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| WO2006013546A2 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Process for the preparation of pure galantamine |
| RU2491067C2 (ru) * | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| CN102573848A (zh) * | 2009-04-24 | 2012-07-11 | 济州大学校产学协力团 | 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物 |
| KR101037235B1 (ko) | 2009-04-24 | 2011-05-25 | 충남대학교산학협력단 | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 |
| KR101037237B1 (ko) | 2009-04-24 | 2011-05-25 | 충남대학교산학협력단 | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643905A (en) * | 1993-01-23 | 1997-07-01 | Therapie-System Gmbh & Co., Kg | Pharmaceutical formulation for the treatment of nicotine dependence |
| US5877172A (en) * | 1995-03-17 | 1999-03-02 | Lts Lohmann Therapie-Systeme Gmbh | Process for isolating galanthamine |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| US20040116406A1 (en) * | 2001-04-24 | 2004-06-17 | Klaus Opitz | Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| DE69229781T2 (de) * | 1991-05-14 | 2000-01-05 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
| US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| ES2223049T3 (es) * | 1994-04-29 | 2005-02-16 | Pfizer Inc. | Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores. |
| PL181582B1 (pl) * | 1995-06-07 | 2001-08-31 | Ortho Mcneil Pharm Inc | Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL |
| US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
| GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
| DK1024807T3 (da) * | 1997-08-08 | 2003-08-04 | Medosan Ricerca Srl | Anvendelse af forbindelsen 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamidoacetat for fremstilling af et anti-inflammatorisk medikament med forhindring af gastrisk hypersecernering og forstyrrelse af nyrefunktionen |
| US5948433A (en) * | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| DE19738855C2 (de) * | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
| JP3992806B2 (ja) * | 1997-12-12 | 2007-10-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ドネペジル中間体の製造法 |
| IL125809A (en) * | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
| DE60124730T2 (de) * | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| WO2002049459A1 (en) * | 2000-12-20 | 2002-06-27 | Michigan Biotechnology Institute | Soy milk juice beverage |
| WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| JP2004189706A (ja) * | 2002-12-13 | 2004-07-08 | Eisai Co Ltd | 高度アルツハイマー型痴呆治療剤 |
| US20050018839A1 (en) * | 2003-07-23 | 2005-01-27 | Weiser William Bruce | Electronic device cradle organizer |
-
2004
- 2004-02-26 CA CA002516618A patent/CA2516618A1/en not_active Abandoned
- 2004-02-26 JP JP2006502684A patent/JP2006519225A/ja active Pending
- 2004-02-26 AU AU2004216360A patent/AU2004216360B2/en not_active Ceased
- 2004-02-26 WO PCT/JP2004/002301 patent/WO2004075916A1/en not_active Ceased
- 2004-02-26 EP EP04714961A patent/EP1603595B1/en not_active Expired - Lifetime
- 2004-02-26 DE DE602004029993T patent/DE602004029993D1/de not_active Expired - Lifetime
- 2004-02-26 AT AT04714961T patent/ATE487492T1/de not_active IP Right Cessation
- 2004-02-26 US US10/493,488 patent/US20060058336A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643905A (en) * | 1993-01-23 | 1997-07-01 | Therapie-System Gmbh & Co., Kg | Pharmaceutical formulation for the treatment of nicotine dependence |
| US5877172A (en) * | 1995-03-17 | 1999-03-02 | Lts Lohmann Therapie-Systeme Gmbh | Process for isolating galanthamine |
| US20040116406A1 (en) * | 2001-04-24 | 2004-06-17 | Klaus Opitz | Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
Non-Patent Citations (4)
| Title |
|---|
| BOROWSKI, T. et al. Society for Neuroscience Abstracts. Vol. 26(1-2) Abstract No. 293.18 * |
| KRUSZEWSKA, A et al. Acta Poloniae Pharmaceutica. Vol.41(3): 381-384, 1985 * |
| MAJEWSKA, M. et al. Society for Neuroscience Abstracts. Vol.26(1-2) Abstract No. 681.3 * |
| WONG, C et al. European Journal of Pharmacology. Vol.56: 115-121, 1979 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060058336A1 (en) | 2006-03-16 |
| WO2004075916A1 (en) | 2004-09-10 |
| EP1603595A4 (en) | 2008-04-16 |
| EP1603595A1 (en) | 2005-12-14 |
| JP2006519225A (ja) | 2006-08-24 |
| DE602004029993D1 (de) | 2010-12-23 |
| AU2004216360A1 (en) | 2004-09-10 |
| CA2516618A1 (en) | 2004-09-10 |
| EP1603595B1 (en) | 2010-11-10 |
| AU2004216360A2 (en) | 2004-09-10 |
| ATE487492T1 (de) | 2010-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3778923B2 (ja) | ベンゾジアゼピンによる治療における改善 | |
| US5039680A (en) | New use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| US5198459A (en) | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| JPH06507617A (ja) | 疲労症候群の治療 | |
| Seidel et al. | Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat. | |
| JP2011057700A (ja) | 神経変性を処置するためのα2Bまたは2B/2Cアドレナリン受容体アゴニスト | |
| EP1603595B1 (en) | Pharmaceutical composition for treatment of drug dependence | |
| JP2007502297A (ja) | コリンエステラーゼ阻害剤を用いる睡眠障害の処置 | |
| US6670356B2 (en) | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors | |
| CA2262612A1 (en) | Method for treating mental retardation | |
| Bowersox et al. | SNX-111 | |
| US6117890A (en) | Method for treating bipolar disorder | |
| EP0821955B1 (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder | |
| US5519044A (en) | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| EP1559447A1 (en) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism | |
| Aceto | The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties | |
| US20230201217A1 (en) | 18-mc for treatment of substance use disorders | |
| US20250367189A1 (en) | 2-bromo-lysergic acid diethylamide for substance abuse | |
| US6090829A (en) | Method for treating excessive aggression | |
| CA2261676A1 (en) | Method for treating excessive aggression | |
| Mason Jr | Dynorphin A peptide involvement in the development of tolerance to Delta9-tetrahydrocannabinol-induced antinociception | |
| HK1008932A (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol -3-yl)-1,2,5,6,-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder | |
| MXPA99001029A (en) | Method for treating bipolar disorder | |
| HK1008931A (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline ) for treating excessive aggression | |
| HK1081880B (en) | Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 AUG 2005 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: DELETE COINVENTOR PASTAN, IRA |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAR 2007 |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: EISAI R & D MANAGEMENT CO., LTD. Free format text: FORMER APPLICANT(S): SHIRANKAI KYOTO UNIVERSITY FACULTY OF MEDICINE ALUMNI ASSOCIATION INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |